A Growing Need for RWE in China

The production of RWE has been proliferating in China over several years, increasing the need for support regarding healthcare and policy decisions unique to China.
We offer complete life-cycle services for RWE-based strategies, including clinical development, regulatory submissions, market access to medical communication leveraging high-quality real-world data, and innovative technologies. We partner with life science companies, and we make innovative therapies accessible to patients and generate better healthcare outcomes in China.

Our Offerings

Degree of evidence demand

Clinical decision Payer decision Regulatory decision
Development
Post-market growth period
Maturity period
Learning about the
current status of treatment
Design of Phase Ⅲ
clinical trial
Patient recruitment
Current status of
treatment & disease burden
Budget impact &
Cost effectiveness
PAC & PASS
Use of medical
resources
Prescription habit
Compliance study
Long-term
effectiveness tracking
Head-to-head
effectiveness evaluation
Exploring the
effectiveness
of subdivided group
Exploring new
indications’
effectiveness
Differentiation
of clinical usage
Treatment pattern
& effectiveness
Differentiation
of generic drugs

Launch

Conditional Pricing
Review

New Competition

New Formulation/
Indication

Competitor Goes Generic

What we do

Retrospective Study

AI-driven evidence solution

Evaluation of prognostic factors

Treatment pattern study

Comparative effectiveness

Safety study

Compliance analysis

Efficacy confirmation of subdivided groups

Disease burden and healthcare resources utilization

Patient-centered Research

Optimized study design & flexible execution
Patient’s preference & willingness to pay

Patient’s preference on treatment plans

Patient’s expected outcomes

Patient’s WTP

Patient-Reported Outcome (PRO)

Quality of Life Scale

Prospective /Registry Study

Intelligent management of
automatic multi-source data
collection technology

Disease registry

Product registry

Post approval safety surveillance (PASS)

Drug intensive monitoring (DIM)

Post authorization commitment (PAC)

Contact us